Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP in Group 3 Pulmonary Hypertension
NCT05716984Phase 4Unknown
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of nesiritide in Pulmonary hypertension due to lung disease and/or hypoxia, sponsored by Shengjing Hospital of China Medical University. Status: unknown.
02
Drugs
nesiritide
03
Conditions
Pulmonary hypertension due to lung disease and/or hypoxia
Beyond the preview
Go deeper on NCT05716984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716984.